SEB Asset Management AB Buys Shares of 31,235 Solventum Corporation $SOLV

SEB Asset Management AB bought a new position in Solventum Corporation (NYSE:SOLV) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 31,235 shares of the company’s stock, valued at approximately $2,040,000.

Several other hedge funds have also recently modified their holdings of SOLV. Independent Franchise Partners LLP raised its position in Solventum by 19.0% in the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after buying an additional 2,456,451 shares during the last quarter. State Street Corp raised its holdings in shares of Solventum by 2.0% during the fourth quarter. State Street Corp now owns 6,344,761 shares of the company’s stock valued at $502,759,000 after purchasing an additional 124,490 shares during the last quarter. Davis Selected Advisers lifted its position in Solventum by 12.7% during the fourth quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock valued at $492,880,000 after purchasing an additional 702,461 shares during the period. Boston Partners lifted its position in Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after purchasing an additional 959,543 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Solventum by 20.0% in the fourth quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock worth $362,375,000 after purchasing an additional 763,308 shares during the last quarter.

Solventum Trading Down 0.4%

Shares of SOLV stock opened at $77.29 on Friday. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $88.20. The firm has a fifty day moving average price of $77.39 and a 200-day moving average price of $74.20. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. The company has a market cap of $13.39 billion, a price-to-earnings ratio of 9.47, a PEG ratio of 1.20 and a beta of 0.66.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.35 by $0.13. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.Solventum’s revenue was down 3.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, equities analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on SOLV. Piper Sandler cut their target price on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Wedbush assumed coverage on Solventum in a research note on Friday, May 15th. They issued an “outperform” rating and a $94.00 price target on the stock. UBS Group cut Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research report on Thursday, May 14th. Wells Fargo & Company lowered their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 6th. Finally, Weiss Ratings raised Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, July 17th. Six investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Solventum presently has a consensus rating of “Hold” and an average target price of $81.91.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.